1. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model

   • Takafumi Yamamoto
   • Fumiko Arakawa
   • Masahide Kuroki

   ORIGINAL ARTICLE Pages: 165 - 171

2. Efficacy of repeated cycles of chemo-immunotherapy with Thymosin α1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery

   • Gianfranco Silecchia
   • Enrico Guarino
   • Guido Rasi

   ORIGINAL ARTICLE Pages: 172 - 178

3. Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: in vitro and in vivo studies

   • Benny Leshem
   • Yael Dorfman
   • Eli Kedar

   ORIGINAL ARTICLE Pages: 179 - 188

4. Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide

   • Tatsuo Fujie
   • Fumiaki Tanaka
   • Tsuyoshi Akiyoshi

   ORIGINAL ARTICLE Pages: 189 - 194

5. Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex

   • Ursula Grohmann
   • Maria Laura Belladonna
   • Paolo Puccetti

   ORIGINAL ARTICLE Pages: 195 - 203

6. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3⁺, CD4⁺, and CD8⁺renal-cell-carcinoma-infiltrating lymphocytes

   • Ursula Elsässer-Beile
   • Thomas Grussenmeyer
   • Jürgen Schulte Mönting

   ORIGINAL ARTICLE Pages: 204 - 208

7. Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity

   • C. Lehmann
   • B. Glass
   • L. Uharek

   ORIGINAL ARTICLE Pages: 209 - 213

8. Prerequisites for the Immunotherapy of Cancer

   • Graham Pawelec
   • Andrea Engel
   • Medi Adibzadeh

   SYMPOSIUM SERIES Pages: 214 - 217